vTv TherapeuticsFRA:5VT0 +1.95%35 Quick Ratio is 14.36 as of Mar. 2026, which is 604% above its 10-year median of 2.04. GuruFocus rates FRA:5VT0 with a GF Score™ of 35/100 and a GF Value™ of €7,126.05. Among 1,416 Biotechnology companies, vTv Therapeutics ranks better than 86.58% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. vTv Therapeutics's quick ratio for the quarter that ended in Mar. 2026 was 14.36.
vTv Therapeutics has a quick ratio of 14.36. It generally indicates good short-term financial strength.
The historical rank and industry rank for vTv Therapeutics's Quick Ratio or its related term are showing as below:
FRA:5VT0'
s Quick Ratio Range Over the Past 10 Years
Min: 0.18 Med: 2.04 Max: 14.36
Current: 14.36
During the past 13 years, vTv Therapeutics's highest Quick Ratio was 14.36. The lowest was 0.18. And the median was 2.04.
FRA:5VT0's Quick Ratio is ranked better than 86.58% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs FRA:5VT0: 14.36
vTv Therapeutics (FRA:5VT0) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
vTv Therapeutics Quick Ratio Related Terms
vTv Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for vTv Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5VT0 vs CRDF, GUTS, ACOG: Quick Ratio Comparison
For the Biotechnology subindustry, vTv Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
vTv Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where vTv Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
vTv Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
vTv Therapeutics (FRA:5VT0) has a Quick Ratio of 14.36 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on vTv Therapeutics and its competitors. This is 604% above median its historical median of 2.04. Over the past decade, vTv Therapeutics' Quick Ratio has ranged from 0.18 to 14.36. According to the industry distribution chart, vTv Therapeutics ranks #190 out of 1416 companies in the Biotechnology industry, placing it in the top 13.4%.
Is vTv Therapeutics' Quick Ratio too high?
vTv Therapeutics' current Quick Ratio of 14.36 is 604% above median its 10-year median of 2.04. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 14.36. The Biotechnology industry median Quick Ratio is 3.60. vTv Therapeutics' value of 14.36 is 298.9% above this industry median. Based on the distribution chart, vTv Therapeutics ranks #190 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, vTv Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' Quick Ratio compare to CRDF and GUTS?
According to the Biotechnology industry distribution chart, vTv Therapeutics ranks #190 out of 1416 companies for Quick Ratio. This places vTv Therapeutics in the top 13% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. vTv Therapeutics' value of 14.36 is 298.9% above this benchmark. Historically, vTv Therapeutics' own Quick Ratio has ranged from 0.18 to 14.36 over the past decade. While the company's 10-year median is 2.04 vs. the industry median of 3.60, vTv Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. vTv Therapeutics's current Quick Ratio of 14.36 is 298.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on vTv Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. vTv Therapeutics's current Quick Ratio is 14.36, which is 604% above median its own 10-year median of 2.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current Quick Ratio of 14.36. The stock's GF Value™ is €7,126.05, compared to a current price of €31.40 — trading 99.6% below its estimated fair value. The current Quick Ratio is 14.36, which is 604% above median its 10-year median of 2.04 and 298.9% above the Biotechnology industry median of 3.60. vTv Therapeutics' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current Quick Ratio is 14.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?
Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued.
The current stock price of €31.40 is trading 99.6% below its estimated GF Value™ of €7,126.05.
Key valuation signals for FRA:5VT0:
Quick Ratio: 14.36 (604% above median its 10-year median of 2.04)
GF Value™: €7,126.05 vs. price of €31.40 (99.6% below fair value)
Industry Position: 298.9% above the Biotechnology median (#190 of 1416)
No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score
Get the complete analysis for FRA:5VT0
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5VT0 has been successfully added to your 
